Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin-tazobactam and vancomycin.

Rutter WC, Hall RG, Burgess DS.

Am J Health Syst Pharm. 2019 Aug 1;76(16):1211-1217. doi: 10.1093/ajhp/zxz120.

PMID:
31369116
2.

Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae.

Kulengowski B, Rutter WC, Campion JJ, Lee GC, Feola DJ, Burgess DS.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):262-266. doi: 10.1016/j.diagmicrobio.2018.06.013. Epub 2018 Jun 22.

PMID:
30098852
3.

Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.

Rutter WC, Burgess DS.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00264-18. doi: 10.1128/AAC.00264-18. Print 2018 Jul.

4.

Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.

Cotner SE, Rutter WC, Burgess DR, Wallace KL, Martin CA, Burgess DS.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00871-17. doi: 10.1128/AAC.00871-17. Print 2017 Oct.

5.

Erratum for Rutter et al., Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.

Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00314-17. doi: 10.1128/AAC.00314-17. Print 2017 Apr. No abstract available.

6.

Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Rutter WC, Burgess DS.

Pharmacotherapy. 2017 May;37(5):593-598. doi: 10.1002/phar.1918. Epub 2017 Apr 20.

7.

Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis.

Rutter WC, Burgess DR, Talbert JC, Burgess DS.

J Hosp Med. 2017 Feb;12(2):77-82. doi: 10.12788/jhm.2684.

8.

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

Crass RL, Rutter WC, Burgess DR, Martin CA, Burgess DS.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02329-16. doi: 10.1128/AAC.02329-16. Print 2017 Apr.

9.

Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.

Rutter WC, Cox JN, Martin CA, Burgess DR, Burgess DS.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e02089-16. doi: 10.1128/AAC.02089-16. Print 2017 Feb. Erratum in: Antimicrob Agents Chemother. 2017 Mar 24;61(4):.

10.

Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.

Rutter WC, Burgess DR, Burgess DS.

Microb Drug Resist. 2017 Jan;23(1):51-55. doi: 10.1089/mdr.2016.0048. Epub 2016 Jun 21.

PMID:
27326758
11.

Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients.

Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS.

J Cyst Fibros. 2016 Sep;15(5):660-3. doi: 10.1016/j.jcf.2016.04.002. Epub 2016 May 4.

Supplemental Content

Loading ...
Support Center